menu
    • menu
    [{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Not Applicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fosifloxuridine Nafalbenamide

    Menu

    Fosifloxuridine Nafalbenamide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NuCana

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            NuCana

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

                            Details : NUC-3373 (fosifloxuridine nafalbenamide), a new chemical entity derived from the nucleoside analog 5-fluorouracil, continues rapid development with multiple data readouts and dosing of first patients in Phase 3 colorectal cancer study.

                            Brand Name : NUC-3373

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NuCana

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            NuCana

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Color...

                            Details : 10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of...

                            Brand Name : NUC-3373

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 15, 2021

                            Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth